Barclays upgraded Centene (CNC) to Overweight from Equal Weight with a price target of $54, up from $44. The firm cites the company’s “attractive” Affordable Care Act exchange margin upside for the upgrade. Barclays’ ACA pricing analysis reinforces its confidence that Centene is best positioned to improve margins by “balancing strong absolute premium increases with stable competitive positioning,” the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC:
- Trump Trade: Trump strikes deals with nine drugmakers to cut prices
- President Trump says he’ll meet with insurance companies on price cuts
- Consumers left in limbo as ACA subsidies are not renewed, WSJ says
- Cantor Fitzgerald says CMS guidance reinforces 2026 as ‘difficult for Medicaid’
- Republican lawmakers have yet to agree on healthcare plan, WSJ reports